June 8, 2026 · Annals of internal medicine · DOI: 10.7326/ANNALS-25-04820

Continuing Glucagon-Like Peptide-1 Receptor Agonists Into the First Trimester of Pregnancy and Pregnancy Outcomes : A Target Trial Emulation Study Using Claims Information

Listen to this summary

The authors aimed to assess the risks associated with continuing glucagon-like peptide-1 receptor agonists (GLP-1RAs) during the first trimester of pregnancy, specifically focusing on nonlive birth, abnormal fetal growth, and major congenital malformations (MCM). Their analysis of claims data from 3,572 pregnancies indicated that continuation of GLP-1RAs did not show definitively higher risks for these outcomes compared to noncontinuation, although the estimates for MCM and small for gestational age (SGA) were imprecise and could not rule out clinically significant differences.

Jeremy P Brown, Krista F Huybrechts, Loreen Straub, Elisabetta Patorno, Ellen W Seely, Brian T Bateman, Sonia Hernández-Díaz

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play